The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | The evolution of lung cancer treatment
Roy S. Herbst, MD, PhD, Yale School of Medicine, New Haven, CT, describes how lung cancer treatment has reached a stage where the best multi-modality therapies (surgery, radiation, chemotherapy, supportive care etc.) to remove tumors. The addition of targeted therapy, such as neo-adjuvant and adjuvant immunotherapy, has improved survival rates for patients and led them to remain disease-free from lung cancer for many years. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
